140 related articles for article (PubMed ID: 17237697)
1. Newly recognized ocular side effects of erlotinib.
Methvin AB; Gausas RE
Ophthalmic Plast Reconstr Surg; 2007; 23(1):63-5. PubMed ID: 17237697
[TBL] [Abstract][Full Text] [Related]
2. Temporal dependence of the effect of radiation on erlotinib-induced skin rash.
Lacouture ME; Hwang C; Marymont MH; Patel J
J Clin Oncol; 2007 May; 25(15):2140; author reply 2141. PubMed ID: 17513824
[No Abstract] [Full Text] [Related]
3. Periocular cutaneous toxicity and cicatricial ectropion: a potential class effect of antineoplastic agents that inhibit EGFR signaling.
Frankfort BJ; Garibaldi DC
Ophthalmic Plast Reconstr Surg; 2007; 23(6):496-7. PubMed ID: 18030130
[No Abstract] [Full Text] [Related]
4. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
Gridelli C; Maione P; Amoroso D; Baldari M; Bearz A; Bettoli V; Cammilluzzi E; Crinò L; De Marinis F; Di Pietro FA; Grossi F; Innocenzi D; Micali G; Piantedosi FV; Scartozzi M
Crit Rev Oncol Hematol; 2008 May; 66(2):155-62. PubMed ID: 18083041
[TBL] [Abstract][Full Text] [Related]
6. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
7. FDA drug approval summary: erlotinib (Tarceva) tablets.
Cohen MH; Johnson JR; Chen YF; Sridhara R; Pazdur R
Oncologist; 2005 Aug; 10(7):461-6. PubMed ID: 16079312
[TBL] [Abstract][Full Text] [Related]
8. Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.
Bidoli P; Cortinovis DL; Colombo I; Crippa A; Cicchiello F; Villa F; Cazzaniga ME; Altomare G
J Thorac Oncol; 2010 Oct; 5(10):1662-3. PubMed ID: 20871265
[TBL] [Abstract][Full Text] [Related]
9. Sparing of previously irradiated skin from erlotinib-induced acneiform rash.
Yalçin S; Dizdar O; Yalçin B; Gököz O
J Am Acad Dermatol; 2008 Jan; 58(1):178-9. PubMed ID: 18158935
[No Abstract] [Full Text] [Related]
10. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases.
Saint-Jean A; Sainz de la Maza M; Morral M; Torras J; Quintana R; Molina JJ; Molina-Prat N
Ophthalmology; 2012 Sep; 119(9):1798-802. PubMed ID: 22584020
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib-induced skin rash in patients with non-small-cell lung cancer: pathogenesis, clinical significance, and management.
Tsimboukis S; Merikas I; Karapanagiotou EM; Saif MW; Syrigos KN
Clin Lung Cancer; 2009 Mar; 10(2):106-11. PubMed ID: 19362953
[TBL] [Abstract][Full Text] [Related]
12. Rapid onset of conjunctivitis associated with overdosing of erlotinib.
Sun P; Long J; Chen P; He Q; Gao X; Li S
J Clin Pharm Ther; 2018 Apr; 43(2):296-298. PubMed ID: 29069525
[TBL] [Abstract][Full Text] [Related]
13. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
Siegel-Lakhai WS; Beijnen JH; Schellens JH
Oncologist; 2005 Sep; 10(8):579-89. PubMed ID: 16177282
[TBL] [Abstract][Full Text] [Related]
14. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Tammaro KA; Baldwin PD; Lundberg AS
J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib or gefitinib for non-small-cell lung cancer.
Yusuf SW; Kim P; Durand JB
N Engl J Med; 2011 Jun; 364(24):2367; author reply 2368. PubMed ID: 21675910
[No Abstract] [Full Text] [Related]
16. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
Herbst RS; Sandler A
Oncologist; 2008 Nov; 13(11):1166-76. PubMed ID: 18997180
[TBL] [Abstract][Full Text] [Related]
17. The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects.
Gerber PA; Enderlein E; Homey B
J Clin Oncol; 2008 Jun; 26(16):2790-2. PubMed ID: 18509193
[No Abstract] [Full Text] [Related]
18. Erlotinib-associated trichomegaly.
Lane K; Goldstein SM
Ophthalmic Plast Reconstr Surg; 2007; 23(1):65-6. PubMed ID: 17237698
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
20. Palmar bullous blistering induced by erlotinib.
Berg A; Brustugun OT; Lund-Iversen M; Helland Å
J Thorac Oncol; 2011 May; 6(5):954. PubMed ID: 21623268
[No Abstract] [Full Text] [Related]
[Next] [New Search]
